Board of Directors

B.J. Cassin  -  Mr. Cassin has served as Chairman of the Board since December 1992. He has been a private venture capitalist since 1979. Previously, Mr. Cassin co-founded Xidex Corporation, a manufacturer of data storage media, in 1969. He is currently a director of PDF Solutions, Inc., as well as a number of private companies.

Timothy B. Anderson  -  Mr. Anderson has served as a member of our Board since 2003. He was Senior Vice President of Strategy and Business Development of Baxter International, Inc., a pharmaceutical company, from 1999 until 2002, and held various management positions at Baxter International from 1992 to 1999, including President, Biotech Group from 1992 until 1997, Group Vice President from 1993 until 1997 and Chairman, Baxter Europe from 1997 until 1999. Mr. Anderson is currently a director of Lake Forest Hospital and a member of the Scientific Advisory Board of Baxter International.

Laurence M. Corash, M.D.  -  Dr. Corash, one of our co-founders, has served as a member of our Board since December 2002. He was appointed Chief Scientific Officer in 2009, and has held various medical positions within the company, including Chief Medical Officer, since 1994. Dr. Corash was a consultant to us from 1991 to 1994. He has been a Professor of Laboratory Medicine at the University of California, San Francisco since July 1985 and was Chief of the Hematology Laboratory for the Medical Center at the University of California, San Francisco from 1982 to 1997. From February 1990 to July 1994, Dr. Corash was a consultant to the FDA Advisory Panel for Hematology Devices. He currently serves on the U.S. Health and Human Services' Advisory Committee on Blood Safety and Availability.

Bruce C. Cozadd  -  Mr. Cozadd has served as a member of our Board since November 2001. He serves as Chairman and Chief Executive Officer of Jazz Pharmaceuticals, Inc., a pharmaceutical company that he co-founded in 2003. Mr. Cozadd was Executive Vice President and Chief Operating Officer of ALZA Corporation, a pharmaceutical company, from 2000 until 2001, and held various management positions at ALZA from 1991 to 2000, including Senior Vice President and Chief Financial Officer. Previously, he was a member of the health care investment banking team at Smith Barney, Harris Upham & Co. Mr. Cozadd currently serves on the boards of directors of Threshold Pharmaceuticals, a biotechnology company, and Nueva School and Stanford Hospital and Clinics, both non-profit institutions.

Claes Glassell  -  Mr. Glassell was appointed our President & Chief Executive Officer and was elected as a member of our Board in May, 2004. Mr. Glassell was President, Chief Operating Officer and a director of Cambrex Corporation from July 2001 until January 2003, and held management positions at Cambrex from 1994 to 2001, including Executive Vice President and Chief Operating Officer from 2000 until 2001 and Vice President and Managing Director of Cambrex Limited from 1994 until 2000. Previously, he was President and Chief Executive Officer of the Pharma Chemistry Business Area of Akzo Nobel and held various international management assignments with Berol in the United States, United Kingdom and Sweden. Mr. Glassell served on the Board of the Swedish Chemical Industry Association from 1993 to 1996 and was also a member of the Responsible Care Committee for the Swedish Chemical Industry Association. He currently serves on the board of directors of CMC Biopharmaceuticals A/S, a contract manufacturing organization.

William R. Rohn  -  Mr. Rohn has served as a member of our Board since March 2002. He was Chief Operating Officer of Biogen Idec, a biotechnology company, from 2003 to 2005. From 1998 to 2003, Mr. Rohn was President and Chief Operating Officer of IDEC Pharmaceuticals, a biotechnology company. He joined IDEC in 1993 as Senior Vice President, Commercial and Corporate Development and was appointed Senior Vice President, Commercial Operations in 1996. From 1984 until 1993, Mr. Rohn was employed by Adria Laboratories, a pharmaceutical company, most recently as Senior Vice President of Sales and Marketing. He serves on the boards of directors of Pharmacyclics, Inc., a pharmaceutical company, Metabasis Therapeutics Inc., a pharmaceutical company, and Raven Biotechnologies, Inc., a biotechnology company.

Gail Schulze  -  Ms. Schulze has served as a member of our Board since October 2007. She is currently Chairman and CEO of Zosano Pharma, a private late-stage transdermal drug delivery company. Prior to joining Zosano, she was CEO of YM Biosciences US and president, YM Biosciences, Inc., a global biopharmaceutical organization. Prior to joining YM Biosciences in 2006, she was president, CEO and director of Eximias Pharmaceutical Corporation. From 2001 to 2004, Ms. Schulze was COO and deputy CEO of Aventis Behring LLC, an independent biologics subsidiary of Aventis, and from 1997 to 2001, was senior executive vice president and chief commercial officer. From 1996 to 1997 she was corporate vice president of Allegiance Healthcare Corporation and from 1979 to 1996 Ms. Schulze held multiple positions within Baxter Healthcare Corporation, most recently as president of the US Managed Care division and president of Renal Division Europe.  Ms. Schulze has served on multiple private and public boards of companies focusing on medical technology and chronic therapy market development.